Teva Pharma (TEVA) PT Lowered to $9 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Price: $41.91 --0%
Rating Summary:
21 Buy, 19 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
21 Buy, 19 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Cantor Fitzgerald analyst Louise Chen lowered the price target on Teva Pharma (NYSE: TEVA) to $9.00 (from $16.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva Pharma (TEVA) PT Raised to $57 at TD Cowen
- Taiwan Semiconductor Manufacturing Co. Ltd. (2330:TT) (TSM) PT Raised to NT$3,828 at Bernstein SocGen Group
- Arista Networks (ANET) PT Raised to $261; Piper Sandler Reiterates 'Top Pick'
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Cantor Fitzgerald, Louise ChenSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
